Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.

Hdl Handle:
http://hdl.handle.net/10147/302487
Title:
Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.
Authors:
Kissling, E; Valenciano, M; Larrauri, A; Oroszi, B; Cohen, J M; Nunes, B; Pitigoi, D; Rizzo, C; Rebolledo, J; Paradowska-Stankiewicz, I; Jiménez-Jorge, S; Horváth, J K; Daviaud, I; Guiomar, R; Necula, G; Bella, A; O'Donnell, J; Głuchowska, M; Ciancio, B C; Nicoll, A; Moren, A
Affiliation:
EpiConcept, Paris, France. e.kissling@epiconcept.fr
Citation:
Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. 2013, 18 (5): Euro Surveill.
Journal:
Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
Issue Date:
2013
URI:
http://hdl.handle.net/10147/302487
PubMed ID:
23399425
Abstract:
Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre case–control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection patients to swab within seven days of symptom onset. We restricted the study population to those meeting the EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related hospitalisations, number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to achieve acceptable levels of protection.
Item Type:
Article
Language:
en
MeSH:
Adolescent; Adult; Aged; Case-Control Studies; Child; Child, Preschool; Confidence Intervals; Europe; Female; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H3N8 Subtype; Influenza Vaccines; Influenza, Human; Logistic Models; Male; Middle Aged; Nasopharynx; Nose; Reverse Transcriptase Polymerase Chain Reaction; Seasons; Sentinel Surveillance; Treatment Outcome; Vaccination; Young Adult
ISSN:
1560-7917

Full metadata record

DC FieldValue Language
dc.contributor.authorKissling, Een_GB
dc.contributor.authorValenciano, Men_GB
dc.contributor.authorLarrauri, Aen_GB
dc.contributor.authorOroszi, Ben_GB
dc.contributor.authorCohen, J Men_GB
dc.contributor.authorNunes, Ben_GB
dc.contributor.authorPitigoi, Den_GB
dc.contributor.authorRizzo, Cen_GB
dc.contributor.authorRebolledo, Jen_GB
dc.contributor.authorParadowska-Stankiewicz, Ien_GB
dc.contributor.authorJiménez-Jorge, Sen_GB
dc.contributor.authorHorváth, J Ken_GB
dc.contributor.authorDaviaud, Ien_GB
dc.contributor.authorGuiomar, Ren_GB
dc.contributor.authorNecula, Gen_GB
dc.contributor.authorBella, Aen_GB
dc.contributor.authorO'Donnell, Jen_GB
dc.contributor.authorGłuchowska, Men_GB
dc.contributor.authorCiancio, B Cen_GB
dc.contributor.authorNicoll, Aen_GB
dc.contributor.authorMoren, Aen_GB
dc.date.accessioned2013-09-30T10:13:58Z-
dc.date.available2013-09-30T10:13:58Z-
dc.date.issued2013-
dc.identifier.citationLow and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. 2013, 18 (5): Euro Surveill.en_GB
dc.identifier.issn1560-7917-
dc.identifier.pmid23399425-
dc.identifier.urihttp://hdl.handle.net/10147/302487-
dc.description.abstractWithin the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre case–control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection patients to swab within seven days of symptom onset. We restricted the study population to those meeting the EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related hospitalisations, number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to achieve acceptable levels of protection.-
dc.language.isoenen
dc.rightsArchived with thanks to Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletinen_GB
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshCase-Control Studies-
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshConfidence Intervals-
dc.subject.meshEurope-
dc.subject.meshFemale-
dc.subject.meshHospitalization-
dc.subject.meshHumans-
dc.subject.meshInfant-
dc.subject.meshInfant, Newborn-
dc.subject.meshInfluenza A Virus, H3N2 Subtype-
dc.subject.meshInfluenza A Virus, H3N8 Subtype-
dc.subject.meshInfluenza Vaccines-
dc.subject.meshInfluenza, Human-
dc.subject.meshLogistic Models-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNasopharynx-
dc.subject.meshNose-
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction-
dc.subject.meshSeasons-
dc.subject.meshSentinel Surveillance-
dc.subject.meshTreatment Outcome-
dc.subject.meshVaccination-
dc.subject.meshYoung Adult-
dc.titleLow and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.en_GB
dc.typeArticleen
dc.contributor.departmentEpiConcept, Paris, France. e.kissling@epiconcept.fren_GB
dc.identifier.journalEuro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletinen_GB

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.